Tempus AI, Inc. announced a new initiative with Bristol Myers Squibb. This collaboration aims to leverage AI, multimodal real-world data and data science techniques to optimize clinical trial designs and enhance the Probability of Technical & Regulatory Success (PTRS) across five initial clinical trial programs. With Lens, Tempus? AI-enabled analytical platform, BMS and Tempus are applying insights from a vast library of de-identified multimodal records to optimize clinical research and strengthen PTRS across BMS?
development portfolio. This collaboration combines unprecedented scale of real-world data with emerging AI-techniques to pressure test assumptions, characterize complex patient populations, validate control group assumptions, and pinpoint the optimal patient segments most likely to benefit from investigational therapies. This new initiative is supporting key assets in solid tumor oncology, including lung, colon, and prostate cancers.
Beyond oncology, the collaboration extends into neuroscience to accelerate drug development in Alzheimer?s Disease, demonstrating the versatility of the Tempus multimodal database across multiple therapeutic areas. This initiative builds upon the existing work between Tempus and BMS, which includes the deployment of the Next Pathways program across 13 community-based health systems to address care gaps for patients with advanced non-small cell lung cancer (aNSCLC).
